Business Context and Reporting Period
This Form 6-K filing by InterCure Ltd. (InterCure) covers the month of September 2025, specifically dated September 19, 2025. The filing announces a strategic acquisition of Botanico Ltd. (ISHI), an Israeli premium cannabis technology and brand company, to expand InterCure's access to exclusive premium indoor product supply and advanced cultivation technologies.
Key Financial Metrics and Transaction Structure
The filing details a share purchase agreement rather than standard periodic financial results. Key transaction metrics include:
- Total Consideration: 4,513,663 Ordinary Shares of InterCure and 410,599 Options.
- Dilution Impact: The aggregate consideration represents approximately 10% of InterCure's outstanding shares on a fully diluted basis immediately prior to the Initial Closing Date.
- Payment Structure:
- Phase 1 (Initial Closing): Acquisition of 50% of ISHI's issued and outstanding share capital for 2,261,345 Ordinary Shares and 205,710 Options.
- Phase 2 (Additional Closing): Acquisition of the remaining 50% upon the earlier of ISHI achieving three consecutive months of positive operating profitability or 24 months from the initial closing. Consideration: 2,252,317 Ordinary Shares and 204,889 Options.
The filing text does not provide specific values for InterCure's current revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Strategic Developments
The primary material change is the entry into the share purchase agreement with ISHI on September 17, 2025. This transaction is designed to:
- Strengthen InterCure's management capabilities by integrating ISHI founders Omer Layani (CEO) and Dor Hershkovitz (COO) into InterCure's leadership team.
- Support global expansion strategies through ISHI's established partnerships with leading American cannabis operators.
- Convert all existing ISHI share options into InterCure options, maintaining original vesting schedules.
Guidance, Outlook, and Risks
Outlook and Timing: The parties expect the Initial Closing to occur in the first quarter of 2026. This timeline is subject to regulatory approvals from the Israeli Medical Cannabis Agency, Israel Securities Authority, and the Tel Aviv Stock Exchange.
Risks and Contingencies:
- Regulatory Approval: Completion is contingent upon obtaining necessary regulatory approvals.
- Performance Milestone: The second phase of the acquisition is contingent on ISHI achieving three consecutive months of positive operating profitability within 24 months.
- Transfer Restrictions: ISHI Securities Holders are subject to Rule 144 transfer restrictions and a voluntary lock-up period limiting sales to 33% of the daily trading volume of InterCure's Ordinary Shares on Nasdaq following the statutory lock-up lapse.
- Forward-Looking Statements: The filing includes a Safe Harbor statement noting that actual results may differ materially from expectations due to various uncertainties.
Investor Verification Checklist
- Verify the status of regulatory approvals from the Israeli Medical Cannabis Agency, Israel Securities Authority, and Tel Aviv Stock Exchange.
- Confirm the exact closing date of the Initial Closing, currently expected in Q1 2026.
- Review the financial health and operational status of ISHI to assess the likelihood of meeting the profitability milestone for the second phase of the acquisition.
- Monitor the impact of the 10% dilution on InterCure's existing shareholders.
- Check for any updates regarding the voluntary lock-up agreement and its potential effect on share liquidity.